News Search Results
Jul 16, 2026, 12:25 ET Raymond Douglas, MD, PhD, Is First in the Nation to Infuse Newly FDA-Approved Thyroid Eye Disease Treatment, LUMVOA ™ (veligrotug-vvze)
a rare autoimmune condition that can cause proptosis, diplopia, pain, soft tissue inflammation, and, in severe cases, total loss of vision. For ophthalmology and endocrinology audiences, the arrival of another approved targeted therapy is significant because TED treatment has historically relied on corticosteroids,
More news about: Dr. Raymond Douglas, MD, PhD
Jul 14, 2026, 16:30 ET Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
achieve with each of our test offerings."With this approval, Castle has New York State approval for all tests within its dermatology and ophthalmology portfolios, its TissueCypher® test within gastroenterology and its clinical laboratories in Phoenix and Pittsburgh."Too often, patients with
More news about: Castle Biosciences, Inc.
Jul 14, 2026, 09:04 ET AMSURG Expands Portfolio With Acquisition of Five North Carolina Centers
health systems, the organization delivers high-quality patient care across a diverse spectrum of medical specialties, including gastroenterology, ophthalmology and orthopedics. Guided by its core values — Care Deeply, Champion Excellence, Cultivate Integrity and Celebrate Teamwork — AMSURG is committed
More news about: AMSURG Corporation
Jul 14, 2026, 08:01 ET Lexitas Pharma Services and Ocusun Enroll First Patient in a Pilot Study for an Upcoming Phase III Clinical Trial Evaluating Investigational Eye Drop for Age-Related Cataract
global leadership in ophthalmology through innovative products that address unmet clinical needs, fostering a culture of innovation dedicated to improving vision health worldwide.About Lexitas Pharma ServicesLexitas is the leading full-service ophthalmology clinical research organization
More news about: Lexitas Pharma Services
Jul 13, 2026, 07:30 ET Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research
diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.Headquartered in Dublin, Ireland, Keenova
More news about: Keenova Therapeutics
Jul 13, 2026, 07:00 ET InMode to Report Second Quarter 2026 Financial Results on August 5, 2026, Expects Q2 Revenue Between $95.2M-$95.4M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.Forward-Looking
More news about: InMode Ltd.
Jul 12, 2026, 20:30 ET Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/gastroenterology/ophthalmology/ skin health businesses, bringing economies of scale in specialty fields.About Insilico MedicineInsilico Medicine is a pioneering
More news about: Insilico Medicine
Jul 10, 2026, 08:00 ET Assort Health Launches Frontier Awards to Recognize Healthcare Leaders Transforming Patient Access
dermatology, family practice, orthopedics, and ophthalmology to share implementation lessons and measurable outcomes from deploying AI, including how they captured more patient demand while reducing administrative
More news about: Assort Health
Jul 10, 2026, 07:00 ET InMode Confirms Receipt of Unsolicited Proposal
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology and ophthalmology. For more information about the Company and its wide array of medical technologies, visit www.inmodemd.com.
More news about: InMode Ltd.
Jul 09, 2026, 08:00 ET Astellas to Spotlight New Research for Geographic Atrophy at ASRS 2026 Annual Meeting
in patients with GA secondary to AMD receiving concomitant anti-VEGF therapyMarci English, Senior Vice President, Biopharma and Ophthalmology Development, Astellas Pharma"Geographic atrophy has a substantial impact on patients' daily lives and wellbeing. The data presented
More news about: Astellas Pharma Inc.
Jul 09, 2026, 06:44 ET Happiest Health Announces Launch of Speciality Clinics: Happiest Paediatrics, Happiest Orthopaedics, Happiest Gynaecology, Happiest Endocrinology & Your Personal Physician
Happiest Healthy Ageing (HHA), along with Brainsphere (Counselling, Psychiatry, and Neurology), ENT, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, Dermatology, Cardiology, Urology, Obesity & Weight management will be coming up soon at locations across the city.The Diagnostics business,
More news about: Happiest Health Systems Pvt. Ltd.
Jul 09, 2026, 02:55 ET Dayton Children's Hospital goes live with Sectra's ophthalmology solution to unify imaging across specialties
pediatric cases. "Having all our ophthalmology imaging in one place makes it much easier for clinicians to review and compare a patient's history. And when a case spans multiple specialties, as in oncology where a child may have both radiology and ophthalmology findings, they can access everything
More news about: Sectra
Jul 09, 2026, 02:52 ET Dayton Children's Hospital goes live with Sectra's ophthalmology solution to unify imaging across specialties
pediatric cases. "Having all our ophthalmology imaging in one place makes it much easier for clinicians to review and compare a patient's history. And when a case spans multiple specialties, as in oncology where a child may have both radiology and ophthalmology findings, they can access everything
More news about: Sectra
Jul 08, 2026, 07:00 ET Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis
diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.Headquartered in Dublin, Ireland, Keenova
More news about: Keenova Therapeutics
Jul 07, 2026, 10:00 ET The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical Trials
research studies in oncology, cardiovascular disease, chronic kidney disease, neurodegenerative disease, cell and gene therapy, women's health, and ophthalmology.The alliance is designed to:Expand clinical trial infrastructure to execute more studies faster.Facilitate
More news about: University of Colorado Anschutz
Jul 07, 2026, 09:00 ET LogicGate Strengthens Leadership Team with the Appointment of David Rostov as Chief Financial Officer
extensive track record of scaling high-growth technology companies. He most recently served as co-founder and CFO of Aurion Biotech, a clinical-stage ophthalmology company developing a treatment for one of the leading causes of corneal blindness. Prior, David was CFO of Identity Digital, the largest owner of
More news about: LogicGate
Jul 07, 2026, 08:50 ET Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics/bio-therapeutics
More news about: Piramal Pharma Limited
Jul 07, 2026, 08:36 ET Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics/bio-therapeutics
More news about: Piramal Pharma Limited
Jul 07, 2026, 07:07 ET Healome Therapeutics Closes £2 Million Seed Round Led by Empirical Ventures to Advance Eye-Drop Matrix Technology for Ocular Surface Diseases
Company: Healome TherapeuticsFounded: 2021Headquarters: Birmingham, United KingdomSector: Ophthalmology/ocular drug deliveryFounders: Prof. Liam Grover, Prof. Tony Metcalfe, Dr. Richard Moakes, Dr. Richard WilliamsAmount
More news about: Healome Therapeutics
Jul 07, 2026, 07:07 ET Healome Therapeutics Closes £2 Million Seed Round Led by Empirical Ventures to Advance Eye-Drop Matrix Technology for Ocular Surface Diseases
Company: Healome TherapeuticsFounded: 2021Headquarters: Birmingham, United KingdomSector: Ophthalmology/ocular drug deliveryFounders: Prof. Liam Grover, Prof. Tony Metcalfe, Dr. Richard Moakes, Dr. Richard WilliamsAmount
More news about: Healome Therapeutics
Jul 07, 2026, 02:00 ET GTCR Announces Divestiture of Corza Medical's Biosurgery Business Unit to EQT
Biosurgery business for its next phase of growth, while Corza Medical continues to invest across its surgical technology businesses in Wound Closure, Ophthalmology and Biomedical Textiles.CHICAGO and BOULDER, Colo., July 7, 2026
More news about: GTCR
Jul 06, 2026, 10:02 ET Cincinnati Oculoplastic Surgery Practice AestheticEye Announces New Location, Opening August 2026
a Cincinnati native, completed her ophthalmology residency at the Bascom Palmer Eye Institute and a fellowship in ophthalmic plastic and reconstructive surgery at the Cincinnati Eye Institute. Dr. Pargament earned his medical degree and completed his ophthalmology residency at the University of Cincinnati
More news about: AestheticEye Oculoplastic Surgeons
Jul 01, 2026, 10:44 ET Parker Waichman LLP Files Lawsuits on behalf of Georgia and California Residents Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic
concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks.A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from
More news about: Parker Waichman LLP
Jul 01, 2026, 07:46 ET ONECOMPASS HOLDINGS ANNOUNCES RYAN BLEEKS AS PRESIDENT OF AQUINAS LEADERSHIP GROUP
of experience as a C-suite executive, Board Director, and Sales Executive, with a distinguished track record of leadership and innovation across ophthalmology and optometry. Throughout his career, he has built strong, lasting relationships with physicians and industry leaders, establishing a trusted network
More news about: OneCompass Holdings
Jun 30, 2026, 13:44 ET PARADIGM HEALTH SUBMITS RESPONSE TO FDA'S REAL-TIME CLINICAL TRIALS INITIATIVE RFI, INFORMED BY BIOPHARMA SPONSORS AND PROVIDERS
The conversations explored dozens of trials across multiple therapeutic areas, including cardiometabolic, cardiovascular, immunology, oncology, ophthalmology, and rare disease therapeuticsPotential Trial Sites: Already, more than 25 of Paradigm Health's provider organization partners–including
More news about: Paradigm Health, Inc.